The ABCA2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma epithelial cell line HT29, in which the ABCA2 gene has been disrupted using CRISPR/Cas9-mediated gene editing. This polyclonal format provides a genetically heterogeneous pool of knockout cells, avoiding the limitations of single-cell clonal selection while enabling robust loss-of-function studies. The product is supplied as a live cell population suitable for immediate culture and downstream experimental applications probing ABCA2 function in a colorectal cancer context.
The HT29 host cell line is a well-characterized epithelial model of human colorectal adenocarcinoma, widely employed in cancer biology, drug resistance, and signal transduction research. These cells exhibit adherent growth, express intestinal epithelial markers, and retain key oncogenic signaling features, including constitutively active Wnt/??-catenin signaling due to an APC mutation. The endogenous expression of ABCA2 in HT29 cells makes this line a physiologically relevant background for investigating the role of this transporter in colorectal cancer cell homeostasis and therapeutic response.
ABCA2 encodes an endolysosomal ATP-binding cassette transporter that facilitates the export of cholesterol and phospholipids from late endosomes/lysosomes, thereby maintaining lysosomal lipid homeostasis and membrane integrity. Its expression is regulated by LXR/RXR heterodimers and SREBP2 in response to cellular cholesterol levels. ABCA2 interacts with key lysosomal machinery components, including LAMP1 and NPC1, and its transport function influences lipid raft composition at the plasma membrane. In the Wnt signaling axis, ABCA2-dependent modulation of membrane microdomains can regulate ??-catenin stabilization and nuclear translocation, placing it as a modulator of TCF4-mediated transcription. Furthermore, ABCA2 has been implicated in multidrug resistance by altering intracellular drug sequestration and lysosomal trapping, linking lysosomal lipid handling to chemosensitivity.
Disruption of ABCA2 in HT29 cells is expected to perturb endolysosomal cholesterol trafficking, leading to altered lysosomal morphology and lipid storage, which can be visualized with lysosomotropic dyes such as LysoTracker. The resulting changes in membrane lipid raft organization may attenuate Wnt/??-catenin signal transduction, impacting the expression of Wnt target genes and proliferation of this APC-mutant line. Additionally, loss of ABCA2 may modify intracellular drug distribution and chemosensitivity, making this knockout model a powerful tool for dissecting the intersection of lysosomal biology, cancer signaling, and drug responsiveness in colorectal adenocarcinoma.
This polyclonal ABCA2 knockout product is well-suited for a variety of research applications, including investigation of cholesterol efflux defects in cancer, mechanistic studies of Wnt/??-catenin crosstalk with lipid metabolism, and functional evaluation of ABC transporter-mediated drug resistance. Typical assays include RT-qPCR and western blotting for expression analysis, Sanger sequencing for target verification, cholesterol efflux and LysoTracker staining for lysosomal function, MTT-based drug sensitivity profiling, LAMP1 immunofluorescence, and TOP/FOP Wnt luciferase reporter assays. These cells also facilitate exploration of ABCA2-associated pathways in Alzheimer??s disease and atherosclerosis. For additional information, please contact Ascent Research.
